United Lab gains NMPA approval to market three dosages of Tadalafil Tablets

Bulletin Express07-02

Hong Kong, 2 July 2026—United Lab (The United Laboratories International Holdings Limited) announced that China’s National Medical Products Administration (NMPA) has granted marketing approval for its Tadalafil Tablets in 5 mg, 10 mg and 20 mg strengths, registered under approval numbers H20265009, H20265010 and H20265011 respectively.

The product, developed and manufactured by the Group’s wholly-owned subsidiary Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, is a selective phosphodiesterase type 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED) and ED associated with benign prostatic hyperplasia. United Lab highlighted two clinical advantages versus peer therapies: an extended duration of action of up to 36 hours and efficacy that is not affected by food intake, offering patients greater flexibility in dosing.

Management noted that the regulatory clearance enriches the Group’s product mix and strengthens its competitive position and brand visibility in the men’s health segment. The company reiterated its commitment to ongoing R&D investment aimed at expanding its pharmaceutical pipeline and enhancing long-term innovation capabilities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129412823?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 17:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129412823","market":"hk","top_or_hot":-1,"title":"United Lab gains NMPA approval to market three dosages of Tadalafil Tablets","media":"Bulletin Express","content":"<p>Hong Kong, 2 July 2026—United Lab (The United Laboratories International Holdings Limited) announced that China’s National Medical Products Administration (NMPA) has granted marketing approval for its Tadalafil Tablets in 5 mg, 10 mg and 20 mg strengths, registered under approval numbers H20265009, H20265010 and H20265011 respectively.</p>\n<p>The product, developed and manufactured by the Group’s wholly-owned subsidiary Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, is a selective phosphodiesterase type 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED) and ED associated with benign prostatic hyperplasia. United Lab highlighted two clinical advantages versus peer therapies: an extended duration of action of up to 36 hours and efficacy that is not affected by food intake, offering patients greater flexibility in dosing.</p>\n<p>Management noted that the regulatory clearance enriches the Group’s product mix and strengthens its competitive position and brand visibility in the men’s health segment. The company reiterated its commitment to ongoing R&D investment aimed at expanding its pharmaceutical pipeline and enhancing long-term innovation capabilities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Lab gains NMPA approval to market three dosages of Tadalafil Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Lab gains NMPA approval to market three dosages of Tadalafil Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-02 17:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong, 2 July 2026—United Lab (The United Laboratories International Holdings Limited) announced that China’s National Medical Products Administration (NMPA) has granted marketing approval for its Tadalafil Tablets in 5 mg, 10 mg and 20 mg strengths, registered under approval numbers H20265009, H20265010 and H20265011 respectively.</p>\n<p>The product, developed and manufactured by the Group’s wholly-owned subsidiary Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, is a selective phosphodiesterase type 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED) and ED associated with benign prostatic hyperplasia. United Lab highlighted two clinical advantages versus peer therapies: an extended duration of action of up to 36 hours and efficacy that is not affected by food intake, offering patients greater flexibility in dosing.</p>\n<p>Management noted that the regulatory clearance enriches the Group’s product mix and strengthens its competitive position and brand visibility in the men’s health segment. The company reiterated its commitment to ongoing R&D investment aimed at expanding its pharmaceutical pipeline and enhancing long-term innovation capabilities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"","article_id":"1129412823","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129412823","pubTimestamp":1782985540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong, 2 July 2026—United Lab (The United Laboratories International Holdings Limited) announced that China’s National Medical Products Administration (NMPA) has granted marketing approval for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药"},"translate_title":"联邦制药获NMPA批准上市三个剂量他达拉非片","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"Hong Kong, 2 July 2026—United Lab (The United Laboratories International Holdings Limited) announced that China’s National Medical Products Administration (NMPA) has granted marketing approval for its Tadalafil Tablets in 5 mg, 10 mg and 20 mg strengths, registered under approval numbers H20265009, H20265010 and H20265011 respectively.\nThe product, developed and manufactured by the Group’s wholly-owned subsidiary Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, is a selective phosphodiesterase type 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED) and ED associated with benign prostatic hyperplasia. United Lab highlighted two clinical advantages versus peer therapies: an extended duration of action of up to 36 hours and efficacy that is not affected by food intake, offering patients greater flexibility in dosing.\nManagement noted that the regulatory clearance enriches the Group’s product mix and strengthens its competitive position and brand visibility in the men’s health segment. The company reiterated its commitment to ongoing R&D investment aimed at expanding its pharmaceutical pipeline and enhancing long-term innovation capabilities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129412823","isCrawlerRequest":true}